Article Impact Level: HIGH Data Quality: STRONG Summary of Clinical Cardiology, 46(8), 877–885. https://doi.org/10.1002/clc.24078 Dr. Yong Zhang et al.
Points
- A meta-analysis compared the efficacy and safety of drug-coated balloons (DCBs) and common balloons (CBs) in treating arteriovenous fistula (AVF) stenosis in dialysis patients.
- Results indicated that the DCB group had significantly higher first-stage patency rates at 6 and 12 months post-surgery than the CB group.
- There was no statistically significant difference in all-cause mortality between the two groups at 6 and 12 months.
- DCBs offer a new endovascular treatment for AVF stenosis with improved primary patency rates for target lesions and the ability to delay restenosis.
- The study provides valuable insights for clinical decision-making, suggesting the advantages of DCBs over CBs in the context of AVF stenosis treatment for dialysis patients.
Summary
A recent meta-analysis aimed to assess the safety and efficacy of drug-coated balloons (DCBs) in comparison to common balloons (CBs) for the treatment of arteriovenous fistula (AVF) stenosis in dialysis patients. The analysis involved a comprehensive search of the PubMed, EMBASE, and China National Knowledge Internet (CNKI) databases to identify relevant randomized controlled trials.
The study findings revealed significant advantages associated with the use of DCBs. Specifically, the DCB group exhibited a substantially higher first-stage patency rate of the target lesion at both six months (OR = 2.31, 95% CI: 1.69-3.15, p < .01) and 12 months (OR = 2.09, 95% CI: 1.50-2.91, p < .01) following surgery.
Furthermore, the analysis did not find any statistically significant difference in all-cause mortality between the DCB and CB groups at either the 6-month (OR = 0.85, 95% CI: 0.47-1.52, p = .58) or 12-month (OR = 0.99, 95% CI: 0.60-1.64, p = .97) follow-up points.
These results suggest that DCBs, as a novel endovascular treatment for AVF stenosis, provide enhanced primary patency rates for target lesions and can effectively delay the onset of restenosis without increasing patient mortality. In conclusion, this meta-analysis contributes valuable insights into the ongoing debate regarding the utility of DCBs compared to traditional CBs in AVF stenosis treatment, potentially informing clinical decision-making for dialysis patients.
Link to the article: https://onlinelibrary.wiley.com/doi/10.1002/clc.24078
References Zhang, Y., Yuan, F., Hu, X., Wang, Q., Zou, Z., & Li, Z. (2023). Comparison of drug‐coated balloon angioplasty versus common balloon angioplasty for arteriovenous fistula stenosis: A systematic review and meta‐analysis. Clinical Cardiology, 46(8), 877–885. https://doi.org/10.1002/clc.24078
